PEN - Penumbra, Inc.
Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Penumbra, Inc. (NYSE: PEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,111 shares of the company's stock, valued at approximately $1,614,000. A number of other institutional
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Bank of Nova Scotia boosted its stake in Penumbra, Inc. (NYSE: PEN) by 14,837.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,820 shares of the company's stock after purchasing an additional 210,402 shares during the quarter. Bank
California Public Employees Retirement System lifted its stake in shares of Penumbra, Inc. (NYSE: PEN) by 25.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,421 shares of the company's stock after purchasing an additional 12,108 shares during
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire ALAMEDA, Cal
First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates ALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO).
Bank of New York Mellon Corp decreased its stake in shares of Penumbra, Inc. (NYSE: PEN) by 0.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 246,527 shares of the company's stock after selling 2,129 shares during the
When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical device companies operate within a unique ecosystem and are often easy to overlook.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.
The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM ) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the groundwork for launching computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke globally.
THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
During the quarter, we initiated new Garden positions in Onto Innovation, Baldwin Group and Freshpet. In addition to Compass, we added to our positions in Ollie's Bargain Outlet and Flowserve during the quarter. We ended our investment campaigns in Penumbra, JBT Marel and Parsons during the quarter.
Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.